Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$155.29 USD

155.29
1,094,683

+0.46 (0.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Medtronic Gets CE Mark for Micra AV Pacer to Treat AV Block

With the approval of Medtronic's (MDT) Micra AV, more pacemaker patients will be eligible for a new treatment option.

Abbott's Libre 2 iCGM Gets FDA Nod to Better Manage Diabetes

Abbott's (ABT) FDA-cleared FreeStyle Libre 2 iCGM is the only available system to continuously transmit glucose data with real-time alarms.

Encompass Health to Build Rehabilitation Hospital in Illinois

Encompass Health (EHC) plans to build a rehabilitation facility in Illinois to serve the local community. The healthcare home will be launched in 2022 spring and complement other units in the area.

STERIS (STE) Segmental Growth Robust Amid Coronavirus Woes

As a major landmark for STERIS (STE), in fiscal 2020, the company joined the coveted S&P 500 Index.

Here's Why You Should Hold on to Intuitive Surgical Stock Now

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Here's Why You Should Hold on to Hill-Rom (HRC) Stock for Now

Investors continue to be optimistic about Hill-Rom (HRC) on robust domestic growth as well as solid second-quarter of fiscal 2020 results.

AMN Healthcare (AMN) Introduces New Customizable Offering

AMN Healthcare (AMN) offers a customizable return-to-work solutions as businesses resume operations amid the ongoing pandemic.

Abbott's (ABT) FreeStyle Libre Study Outcome Favorable

The latest study outcome aligns with the American Diabetes Association's recommended A1c level of 7% for adults with diabetes.

Here's Why You Should Add LabCorp (LH) Stock to Your Portfolio

Investors continue to be optimistic about LabCorp (LH) on increasing demand for COVID-19 tests as well as robust first-quarter 2020 results.

Zacks.com featured highlights include: eBay, Quest Diagnostics, Acuity Brands and Vistra Energy

Zacks.com featured highlights include: eBay, Quest Diagnostics, Acuity Brands and Vistra Energy

Aniruddha Ganguly headshot

Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks

Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.

Swayta Shah headshot

4 Stocks With Upgraded Broker Ratings Worth Betting on Now

By following broker ratings, you can find stocks that are likely to generate solid returns.

Trina Mukherjee headshot

Diagnostic Testing Remains Crucial in Combatting Coronavirus

Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.

DGX vs. EHC: Which Stock Should Value Investors Buy Now?

DGX vs. EHC: Which Stock Is the Better Value Option?

Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA

This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.

Why Is Quest Diagnostics (DGX) Up 12.3% Since Last Earnings Report?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

Medical Info Systems Outlook Bright Amid Coronavirus Crisis

Despite the coronavirus-led worldwide sales disruption, Medical Info Systems is one of the few sectors witnessing industry-wide growth.

Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis

Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher

Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Quest Diagnostics' (DGX) Q1 Earnings Beat, Margins Decline

Quest Diagnostics' (DGX) January and February results consistent with its earlier-provided guidance.

Quest Diagnostics (DGX) Surpasses Q1 Earnings and Revenue Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 13.25% and 4.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will COVID-19 Test Aid Quest Diagnostics (DGX) Q1 Earnings?

Quest Diagnostics' (DGX) recently-launched COVID-19 test service anticipated to have contributed to Q1 revenues.

Daniel Laboe headshot

3 Stocks Testing The Coronavirus

If we can test the working population, we will be able to bring the healthy American's back to work and isolate those with the virus